Correlation Between Merck and Kiniksa Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Merck and Kiniksa Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Merck and Kiniksa Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Merck Company and Kiniksa Pharmaceuticals, you can compare the effects of market volatilities on Merck and Kiniksa Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Merck with a short position of Kiniksa Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Merck and Kiniksa Pharmaceuticals.
Diversification Opportunities for Merck and Kiniksa Pharmaceuticals
0.77 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Merck and Kiniksa is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Merck Company and Kiniksa Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kiniksa Pharmaceuticals and Merck is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Merck Company are associated (or correlated) with Kiniksa Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kiniksa Pharmaceuticals has no effect on the direction of Merck i.e., Merck and Kiniksa Pharmaceuticals go up and down completely randomly.
Pair Corralation between Merck and Kiniksa Pharmaceuticals
Considering the 90-day investment horizon Merck Company is expected to generate 0.73 times more return on investment than Kiniksa Pharmaceuticals. However, Merck Company is 1.37 times less risky than Kiniksa Pharmaceuticals. It trades about -0.05 of its potential returns per unit of risk. Kiniksa Pharmaceuticals is currently generating about -0.16 per unit of risk. If you would invest 10,057 in Merck Company on October 5, 2024 and sell it today you would lose (140.00) from holding Merck Company or give up 1.39% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
Merck Company vs. Kiniksa Pharmaceuticals
Performance |
Timeline |
Merck Company |
Kiniksa Pharmaceuticals |
Merck and Kiniksa Pharmaceuticals Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Merck and Kiniksa Pharmaceuticals
The main advantage of trading using opposite Merck and Kiniksa Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Merck position performs unexpectedly, Kiniksa Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiniksa Pharmaceuticals will offset losses from the drop in Kiniksa Pharmaceuticals' long position.The idea behind Merck Company and Kiniksa Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.Kiniksa Pharmaceuticals vs. Nuvalent | Kiniksa Pharmaceuticals vs. Ventyx Biosciences | Kiniksa Pharmaceuticals vs. Arcellx | Kiniksa Pharmaceuticals vs. Cullinan Oncology LLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Complementary Tools
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |